An aromatic amide derivative, a preparation method therefor, and a use of said compound in preventing and/or treating diseases, especially in tumor treatment. The aromatic amide derivative is a MEK/RAF inhibitor having advantages such as relatively good activity and safety, and shows good application prospects in preventing and/or treating tumors related to the MAPK pathway.
A61K 31/166 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome de carbone d'un groupe carboxamide lié directement au cycle aromatique, p. ex. procaïnamide, procarbazine, métoclopramide, labétalol
C07C 307/10 - Diamides d'acides sulfuriques ayant des atomes d'azote des groupes sulfamide liés à des atomes de carbone de cycles aromatiques à six chaînons
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
The present invention specifically relates to a new crystalline form of a urea compound and a preparation method therefor. The crystalline form product has a high solubility in water. The preparation method is simple and has a high yield. The product has stable properties, and is easy to store and transport and later use. The preparation method provided in the present invention has good repeatability in the process, and simple operation, and is suitable for industrial production.
The present invention provides a quinoline-4-base cyclohexane compound, a pharmaceutically acceptable salt, hydrate, solvate or stereoisomer thereof, as well as a preparation method therefor. Said compound alone or in combination with other drugs is used for tretating pathological features of tryptophan metabolic pathway disorders mediated by IDO.
The present invention concerns a quinoline-4-base cyclohexane compound, a pharmaceutically acceptable salt, hydrate, solvate or stereoisomer thereof, as well as a preparation method therefor. Said compound alone or in combination with other drugs is used for treating pathological features of tryptophan metabolic pathway disorders mediated by IDO.
C07D 215/12 - Composés hétérocycliques contenant les systèmes cycliques de la quinoléine ou de la quinoléine hydrogénée ne comportant pas de liaison entre l'atome d'azote du cycle et un chaînon non cyclique ou ne comportant que des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle avec des radicaux hydrocarbonés substitués liés aux atomes de carbone du cycle
Provided is a quinoline-4-base cyclohexane compound, a pharmaceutically acceptable salt, hydrate, solvate or stereoisomer thereof, as well as a preparation method therefor. Said compound alone or in combination with other drugs is used for treating pathological features of a tryptophan metabolic pathway disorder mediated by IDO.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 25/18 - Antipsychotiques, c.-à-d. neuroleptiquesMédicaments pour le traitement de la manie ou de la schizophrénie
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 27/12 - Agents ophtalmiques pour le traitement de la cataracte
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
Disclosed is a quinoline-4-base cyclohexane compound, a pharmaceutically acceptable salt, hydrate, solvate or stereoisomer thereof, as well as a preparation method therefor. Said compound alone or in combination with other drugs is used for treating pathological features of tryptophan metabolic pathway disorders mediated by IDO.
Disclosed is a quinoline-4-base cyclohexane compound, a pharmaceutically acceptable salt, hydrate, solvate or stereoisomer thereof, as well as a preparation method therefor. Said compound alone or in combination with other drugs is used for treating pathological features of tryptophan metaboc pathway disorders mediated by IDO.
brevets